Drug Profile
ETBX 061
Alternative Names: Ad5 MUC1; Adenoviral MUC1 vaccine - Etubics; ETBX-061Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Etubics Corporation
- Developer ImmunityBio; National Cancer Institute (USA)
- Class Antineoplastics; Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Colorectal cancer; Liver cancer; Pancreatic cancer; Triple negative breast cancer
- No development reported Prostate cancer; Solid tumours
Most Recent Events
- 28 May 2021 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Metastatic disease) in USA (SC)
- 09 Mar 2021 National Cancer Institute completes a phase I trial in Prostate cancer (Metastatic disease; Combination therapy) in USA (SC) (NCT03481816)
- 09 Mar 2021 NantKwest has been merged with ImmunityBio to form ImmunityBio